Changing the Subject (Part 4): Project Re-CLAIM
This article was originally published in RPM Report
Rather than try to “win” the drug pricing debate, the biopharma sector may be better served by coming up with new ideas to change the subject. We outlined our case for taking this approach – and the model for ideas that serve that goal – here. Today we offer a proposal suggested by one of our readers: a national project to merge claims and clinical data.